Christophe Nicot, Kansas University Medical Center, USA
2022 Special Issues
- Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments
- Genome Editing and the Future of Personalized and Targeted Cancer Medicine
This special issue published by Molecular Cancer focuses on the clinical aspects of liquid biopsies, in particular validation of novel biomarkers that may serve as signature for non-invasive early detection of cancerous cells, predict patients' risks of disease progression and response to specific therapies.
Molecular Cancer is excited to present a series of original research and review articles related to genome editing and reprogramming.
Aims and scope
Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.
2021 Thematic Series: mRNA therapies and mRNA vaccines in cancer
In this review, Sahebkar et al. summarize the current knowledge on the contribution of the NLRP3 inflammasome on potential cancer promotion and therapy.
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. Molecular Cancer is proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Recognising Editorial Excellence
Molecular Cancer is a top rated Springer Nature journal. Prof. Christophe Nicot and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.
What is trending?
Click here to see which articles published in Molecular Cancer have been shared the most in the past three months.
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
Annual Journal Metrics
48 days to first decision for reviewed manuscripts only
12 days to first decision for all manuscripts
118 days from submission to acceptance
19 days from acceptance to publication
27.401 - 2-year Impact Factor
20.260 - 5-year Impact Factor
4.213 - Source Normalized Impact per Paper (SNIP)
7.274 - SCImago Journal Rank (SJR)
196 Altmetric mentions